The online version of this article (doi:10.1186/ar3422) contains supplementary material, which is available to authorized users.
RWB and TTW are employees of INOVA Diagnostics. All other authors have no competing interests.
MEK, YL, SJR, JYFC, EKLC, RWB, TTW and MS carried out the immunoassays. AC and MS designed the study. MS performed the statistical analysis. MRB, ESS and WHR enrolled patients for the study and maintained the database. AC, MS and EKLC drafted the manuscript. All authors read and approved the final manuscript.
Anti-RNA polymerase III (RNAP III) antibodies are highly specific markers of scleroderma (systemic sclerosis, SSc) and associated with a rapidly progressing subset of SSc. The clinical presentation of anti-RNAP III positive patients, onset of Raynaud's phenomenon (RP) and SSc in unselected patients in a rheumatology clinic were evaluated.
Autoantibodies in sera from 1,966 unselected patients (including 434 systemic lupus erythematosus (SLE), 119 SSc, 85 polymyositis/dermatomyositis (PM/DM)) in a rheumatology clinic were screened by radioimmunoprecipitation. Anti-RNAP III positive sera were also tested by immunofluorescence antinuclear antibodies and anti-RNAP III ELISA. Medical records of anti-RNAP III positive patients were reviewed.
Among 21 anti-RNAP III positive patients, 16 met the American College of Rheumatology (ACR) SSc criteria at the initial visit but 5 did not; diagnoses were vasculitis, early polyarthritis, renal failure with RP, interstitial lung disease, and Sjögren's syndrome. The first two patients developed rapidly progressive diffuse SSc. An additional case presented with diffuse scleroderma without RP and RP developed two years later. Anti-RNAP III antibodies in these 6 cases of atypical clinical presentation were compared with those in 15 cases of typical (SSc with RP) cases. Anti-RNAP III levels by ELISA were lower in the former group (P = 0.04 by Mann-Whitney test) and 3 of 6 were negative versus only 1 of 15 negative in the latter (P < 0.05 by Fisher's exact test). Three cases of non-SSc anti-RNAP III positive patients had predominant reactivity with RNAP I with weak RNAP III reactivity and had a strong nucleolar staining. Three anti-RNAP III patients, who did not have RP at the initial visit, developed RP months later. Scleroderma developed prior to RP in 5 out of 16 (31%) in the anti-RNAP III group, but this was rare in patients with other autoantibodies. The interval between the onset of RP to scleroderma was short in anti-RNAP III positive patients.
Anti-RNAP III antibodies are highly specific for SSc; however, a subset of anti-RNAP III positive patients do not present as typical SSc. The interval between RP and scleroderma in this group is short, and 31% of patients developed scleroderma prior to RP in this group. Anti-RNAP III positive patients may not present as typical SSc and detecting anti-RNAP III may have predictive value.
Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, Reeves WH: Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest. 1994, 94: 1981-1989. 10.1172/JCI117550. PubMedCentralCrossRefPubMed
Reeves WH, Narain S, Satoh M: Autoantibodies in systemic lupus erythematosus. Arthritis and Allied Conditions. A Textbook of Rheumatology. Edited by: Koopman WJ, Moreland LW. 2005, Philadelphia, PA: Lippincott Williams and Wilkins, 1497-1521. 15
Yamasaki Y, Narain S, Hernandez L, Barker T, Ikeda K, Segal MS, Richards HB, Chan EK, Reeves WH, Satoh M: Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. Arthritis Res Ther. 2006, 8: R111-120. 10.1186/ar2000. PubMedCentralCrossRefPubMed
Hirakata M, Okano Y, Pati U, Suwa A, Medsger TAJ, Hardin JA, Craft J: Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III. J Clin Invest. 1993, 91: 2665-2772. 10.1172/JCI116505. PubMedCentralCrossRefPubMed
Phan TG, Cass A, Gillin A, Trew P, Fertig N, Sturgess A: Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma. J Rheumatol. 1999, 26: 2489-2492. PubMed
Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, Kuwana M: Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxford). 2009, 48: 1570-1574. 10.1093/rheumatology/kep290. CrossRef
Parker JC, Burlingame RW, Webb TT, Bunn CC: Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology (Oxford). 2008, 47: 976-979. 10.1093/rheumatology/ken201. CrossRef
Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EK, Reeves WH, Satoh M: Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum. 2006, 54: 3051-3056. 10.1002/art.22043. CrossRefPubMed
Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP: A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford). 2009, 48: 1218-1221. 10.1093/rheumatology/kep215. CrossRef
- Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining
Malgorzata E Krzyszczak
Steven J Ross
Jason YF Chan
Edward KL Chan
Rufus W Burlingame
Tyler T Webb
Michael R Bubb
Eric S Sobel
Westley H Reeves
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II